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For a long time, the most considered cause of atherosclerosis has
been related to a cholesterol storage disorder, characterized by the
deposition of cholesterol in the arterial wall. More recent data
focused the attention on the proliferation and migration of smooth-
muscle cells as well as on blood cells. Over the most recents years,
however, the concept that inflammation may play a key role in the
atherogenesis has been progressively raised, along with the discovery
of the immune basis of allograft arteriosclerosis, which demonstrated
that inflammation per se can drive arterial hyperplasia even in the
absence of traditional risk factors. The understanding of the participa-
tion of inflammation in atherosclerosis cannot reduce the importance
of traditional risk factors as causal pathogenic drivers of cardiovascu-
lar disease, but the validation of these concepts in humans could have
an important impact on medical clinical practice both in prevention
and in treatment.1
To reduce the burden of atherosclerotic diseases, several phar-
macological interventions have been proposed and tested in different
clinical conditions, including those involving high and very high
cardiovascular-risk patients. Although the incidence of major cardio-
vascular events and their severity has been reduced as a result of the
progress in the therapeutic management of the acute conditions, the
occurrence of events and lethality persist in spite of optimal medical
therapy. In particular, scientific and clinical identification of the so-
called residual cardiovascular risk in statin-treated populations has
substantially encouraged further exploration of the key pathophysio-
logical mechanisms of life-threatening vascular events.
Following these studies, atherosclerosis and its complications are
no longer viewed as mere consequences of high levels of cholesterol,
blood pressure, plasma glucose, or cigarette smoking. They are now
considered complex, multifactorial, and progressive disorders, in
which proinflammatory biological pathways are not only involved but
seem to play a major role. These proinflammatory factors may pro-
mote endothelial dysfunction and local inflammation, favoring vascu-
lar wall damage and development of atherosclerotic plaque, which
may significantly contribute to several clinical manifestations.
Since the 1990s, the scientific community identified in elevated
serum high-sensitivity C-reactive protein (hsCRP) levels, a marker of
the vascular inflammatory process that predicts the progression of
atherosclerotic plaque, its recurrent instability, and a worse out-
come.2 It was clear that independently or beside low-density
lipoprotein (LDL) levels, or the concomitant presence of the other risk
factors, hsCRP levels could predict outcomes.3
Results from the JUPITER (Justification for the Use of Statins in
Prevention: An Intervention Trial Evaluating Rosuvastatin),4 PROVE-
IT TIMI-22 (Pravastatin or Atorvastatin Evaluation and Infection
Therapy–Thrombolysis in Myocardial Infarction 22),5 and ASCOT-LLA
(Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm)6
trials demonstrated that serum levels of hsCRP might be considered
as important as levels of LDL-cholesterol (LDL-C) to define the resid-
ual cardiovascular risk in high-risk individuals with hypercholesterol-
emia. In addition, the JUPITER trial demonstrated that those patients
with elevated hsCRP but without hyperlipidemia could significantly
benefit from statin therapy, namely rosuvastatin, in terms of reduced
incidence of major cardiovascular events in a setting of primary car-
diovascular disease prevention.
On the other hand, in a setting of secondary prevention, serum
levels of hsCRP in patients with prior myocardial infarction are pow-
erful predictors of subsequent events. It has been reported that rates
of recurrent events are up to 60% higher in patients with hsCRP
≥2 mg/L compared to those without a high inflammatory burden,
independent from the intensity of statin treatment. Although inten-
sive statins therapy reduces levels of hsCRP, persistently high levels
of this inflammatory marker are common in patients after a myocar-
dial infarction, as reported in the PROVE-IT TIMI-22 trial,5 in which
about 43% of patients randomized to receive atorvastatin 80 mg
daily had on-treatment, persistently high levels of hsCRP.
Starting from these germinal observations as well as from the
further insights derived from these data, the existence of a residual
inflammatory risk has been recently proposed, a condition that is dif-
ferent from the postulated residual cholesterol risk7 and which can-
not be assessed and managed in the same way. This innovative
pathophysiological hypothesis has been validated by Ridker and
coworkers in the recently published results of a proof-of-concept
study, CANTOS (Canakinumab Antiinflammatory Thrombosis Out-
come Study).8
The randomized, double-blind trial assigned patients with a previ-
ous myocardial infarction and elevated levels of hsCRP to receive
canakinumab every 3 months, a human anti-interleukin (IL)-1β mono-
clonal antibody (1 of 3 doses of 50 mg, 150 mg, and 300 mg subcu-
taneously) or placebo. The mean age of patients was 61 years, and
approximately 25% were women. Almost 80% of patients had
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hypertension, about 40% had diabetes, and 22% were current
smokers, with approximately 93% of the patients being treated with
lipid-lowering therapy (91% of patients being treated with a statin). In
addition, most of the participants underwent previous coronary artery
revascularization (66.7% percutaneous coronary intervention and
14% coronary artery bypass). Median levels of total cholesterol, LDL-
C, high-density lipoprotein cholesterol, triglycerides, and hsCRP in
patients treated with canakinumab at different dosages were compa-
rable to those of the placebo group. At the end of the follow-up
period, canakinumab at the dosage of 150 mg significantly reduced
hsCRP levels from baseline, without affecting cholesterol levels, in a
median follow-up of 3.7 years. This resulted into a significantly lower
incidence of recurrent cardiovascular events as compared with pla-
cebo. The incidence rate for the primary endpoint was 4.50 events
per 100 person-years in the placebo group and 3.86 events per
100 person-years in the 150 mg group, with a hazard ratio [HR] of
0.85 and 95% confidence interval [CI] of 0.74–0.98 (P = 0.021 com-
pared to placebo). The significant results observed with the 150-mg
dose were driven by a 24% relative reduction in risk of myocardial
infarction.
The relative hazard reduction of 27% (HR: 0.73, 95% CI: 0.63–
0.83, P < 0.001) of the secondary endpoint, which was observed in
those patients with 3-month on-treatment hsCRP decrease more
than the median value (1.8 mg/L), reveals that this cutoff period
could be useful in an attempt to transfer these data to clinical prac-
tice and to identify the responders to treatment. In a subgroup analy-
sis, the patients who seemed to benefit most from the treatment
were diabetics with a level of hsCRP between 2 and 4 mg/L.
A finding that is consistent with the putative effects of inflamma-
tion in the tumoral microenvironment was the surprisingly significant
reduction in cancer mortality, substantially driven by a 77% reduction
in death from lung cancer with canakinumab 300 mg compared to
placebo. Although this stunning result of CANTOS needs to be con-
firmed by further specific studies, this appears to be the most intrigu-
ing finding of the study due to the unexpectedly large reduction of
death from lung cancer.
There are important issues to be discussed. The trial seems to
identify a potentially new area of therapeutic intervention; in the age
of personalized medicine, not all high-risk secondary-prevention
patients appear to have the same clinical characteristics. We should
focus on individual risk profiles, in the attempt to identify not only
those with residual cholesterol risk but also those with persistently
high proinflammatory response, despite optimal treatment with sta-
tins, who, according to CANTOS results could benefit from anti-
inflammatory treatment. This is a breakthrough discovery, and no
matter whether the treatment based on canakinumab can be trans-
lated to secondary cardiovascular prevention, the road to explore and
to consider the role of anti-inflammatory approach in these patients
in now open.
It is interesting to note that the median body mass index of the
trial participants was at about 29.9, meaning that most patients
included in the trial were overweight, with a high proportion (40%) of
diabetics. This may indirectly support a contributory role of fat tissue
through the release of pro-inflammatory adipokines such as leptin,
cytokines, and chemokines such as tumor necrosis factor-α and IL-6,9
to insulin resistance and low-grade chronic inflammation.
As suggested and shown in the Table 1, based on the results of
subgroups analyses, the typology of patients who could benefit most
are diabetic subjects 30 days after myocardial infarction, with persis-
tently high C-reactive protein serum levels, mostly smokers, and
those on optimal therapeutic treatment. With regard to the side
effects reported in CANTOS, we will need more details on fatal infec-
tions for a better understanding of which clinical parameters (ie, leu-
kopenia), may be used to promptly identify those who are at high risk
for this threatening side effect, thus minimizing the risk of the major
adverse effect of canakinumab.
Finally, the therapeutic approach based on a specific and selec-
tive intervention on the inflammatory cascade that has been adopted
and tested in CANTOS has demonstrated to provide favorable effects
on noncardiovascular morbidity and mortality, particularly in reducing
the risk of cancer, mostly lung malignancies. This result has
two important, though still speculative, consequences. First, these
data support the emerging concept of global risk,10,11 which is biolog-
ically more meaningful than just looking at cardiovascular and neo-
plastic risk, as in separate silos. Second, based on the intriguing
hypothesis that inflammatory pathways are relevant both for patho-
genesis of cardiovascular events and cancer12 (Figure 1), a novel mul-
tiple target therapeutic approach appears conceivable.
CANTOS data provide the evidence of a completely new thera-
peutic target, independent of LDL-C, that may provide a reduction in
cardiovascular recurrent events, opening the field for new preventive
FIGURE 1 Shared risk factors in cardiovascular disease and cancer.
Chronic inflammation may contributes to both disease
TABLE 1 CANTOS-based features that may identify patients eligible
for anti-inflammatory treatment strategies
Predominantly men, age > 60 years
Previous myocardial infarction, STEMI, or NSTEMI
hsCRP >2 mg/L
Diabetes mellitus
Optimal cardiovascular medical treatment
Current or past smoker
Abbreviations: CANTOS, Canakinumab Antiinflammatory Thrombosis
Outcome Study; hsCRP, high-sensitivity C reactive protein; NSTEMI,
non–ST-segment elevation myocardial infarction; STEMI, ST-segment ele-
vation myocardial infarction.
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strategies. At this time, another question that remains open is
whether the high cost of this novel drug is reasonable in view of its
net clinical benefit.
In conclusion, it is necessary to promote other clinical trials to
confirm the benefit in lowering hsCRP levels and to investigate other
population groups with this approach.
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